Steven G. Deeks, MD

Steven G. Deeks, MD

University of California San Francisco

Associate Clinical Professor
University of California San Francisco
Positive Health Program
San Francisco General Hospital
San Francisco, California

Committees and Organizations

  • Committee on Human Research, UCSF
  • Internal Advisory Committee, UCSF Center for AIDS Research
  • Immunology Research Agenda Committee, AIDS Clinical Trials Group
  • HIV Disease Research Agenda Committee, AIDS Clinical Trials Group


  • University of California Berkeley, BS (1981–1986)
  • University of California San Francisco, MD (1986–1990)
  • American Board of Internal Medicine, Board Certification (1993)

Selected Publications

  1. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375-1381.
  2. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
  3. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
  4. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4+ T cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002. In press.
  5. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein M. Incomplete and complete suppression of HIV-1 replication with protease inhibitor-based regimens are associated with similar T cell dynamics and activation. J Infect Dis. 2002. In press.